BNTX
BioNTech SE
Price Chart
Latest Quote
$91.99
+1.59 (+1.76%)
Current Price
| Previous Close | $90.40 |
| Open | $90.00 |
| Day High | $92.23 |
| Day Low | $89.69 |
| Volume | 742,449 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 252.88M |
| Total Debt | $346.57M |
| Cash Equivalents | $15.69B |
| Revenue | $3.21B |
| Net Income | $-1.43B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $23.13B |
| EPS (TTM) | $-5.77 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $9.73B |
| Sales | $3.21B |
| Income | $-1.43B |
| Book/sh | $84.47 |
| Cash/sh | $54.20 |
| Employees | 8K |
Financial Ratios
| Quick Ratio | 8.11 |
| Current Ratio | 8.80 |
| Debt/Eq | 1.62 |
Returns & Margins
| ROA | -4.18% |
| ROE | -6.66% |
| Gross Margin | 78.65% |
| Operating Margin | -576.63% |
| Profit Margin | -44.64% |
Ownership
| Insider Ownership | 57.13% |
| Institutional Ownership | 20.46% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -18.47 |
| PEG | 0.05 |
| P/S | 8.25 |
| P/B | 1.08 |
Analyst Data
| Recommendation | buy |
| Target Price | $122.23 |
Technical Indicators
| SMA20 | $92.18 |
| SMA50 | $91.38 |
| SMA200 | $98.81 |
| RSI | 50.67 |
| ATR | 2.4651 |
| Shares Float | 110.10M |
| Short Float | 3.40% |
| Short Ratio | 2.24 |
| Volatility | 1.32 |
| Rel Volume | 1.35 |
Performance History
| Week | -0.01% |
| Month | +2.21% |
| Quarter | -10.42% |
| 6 Months | -16.17% |
| YTD | -5.39% |
| Year | -18.68% |
| 3 Years | -16.07% |
| 5 Years | -57.36% |
| 10 Years | +550.92% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $91.48 | 1,131,000 |
| 2026-07-16 | $91.56 | 670,200 |
| 2026-07-15 | $91.99 | 761,900 |
| 2026-07-14 | $90.40 | 923,500 |
| 2026-07-13 | $90.07 | 671,500 |
| 2026-07-10 | $91.49 | 551,800 |
| 2026-07-09 | $92.98 | 816,200 |
| 2026-07-08 | $93.53 | 686,500 |
| 2026-07-07 | $94.29 | 895,600 |
| 2026-07-06 | $93.93 | 784,900 |
| 2026-07-02 | $97.54 | 1,390,600 |
| 2026-07-01 | $93.92 | 545,300 |
| 2026-06-30 | $93.05 | 561,300 |
| 2026-06-29 | $94.26 | 935,600 |
| 2026-06-26 | $91.22 | 873,600 |
| 2026-06-25 | $90.00 | 712,700 |
| 2026-06-24 | $90.21 | 1,440,700 |
| 2026-06-23 | $90.62 | 552,900 |
| 2026-06-22 | $90.19 | 887,500 |
| 2026-06-18 | $90.89 | 939,600 |
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
đ° Latest News
Is BioNTech (BNTX) Undervalued As It Exits German Manufacturing Sites?
Simply Wall St. âĸ 2026-07-10T21:10:08Z
BioNTech (BNTX) Stock Could Be Overvalued After a 58% Five Year Slump
Simply Wall St. âĸ 2026-07-10T12:15:42Z
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
MT Newswires âĸ 2026-07-08T15:11:50ZFormer Pfizer Building Is CrumblingâJust as the Stock Has
Barrons.com âĸ 2026-07-07T19:22:00Z
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
MT Newswires âĸ 2026-07-06T15:21:24ZEuropean Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
MT Newswires âĸ 2026-07-02T15:13:34ZVERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026
Exec Edge âĸ 2026-06-18T14:34:10Z
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
Zacks âĸ 2026-06-18T12:16:00Z
US Equity Markets End Lower After Government Bond Yields Rise, Fed's Policy Statement
MT Newswires âĸ 2026-06-17T20:25:56ZSector Update: Healthcare Stocks Retreat Late Afternoon
MT Newswires âĸ 2026-06-17T19:38:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $734,493,056 | $619,478,173 | $686,427,135 | $3,427,557,966 |
| Cost Of Revenue | $734,493,056 | $619,478,173 | $686,427,135 | $3,427,557,966 |
| Total Revenue | $3,284,390,186 | $3,148,432,294 | $4,370,565,567 | $19,810,712,833 |
| Operating Revenue | $3,284,390,186 | $3,148,432,294 | $4,370,565,567 | $19,621,424,657 |
| Expenses | ||||
| Interest Expense | $16,250,859 | $19,340,811 | $8,583,200 | $21,629,665 |
| Total Expenses | $4,017,624,373 | $3,960,288,595 | $3,368,505,549 | $5,729,915,602 |
| Other Income Expense | $-454,909,613 | $55,962,466 | $363,927,691 | $765,850,348 |
| Net Non Operating Interest Income Expense | $-14,419,776 | $-19,684,139 | $-8,583,200 | $-21,629,665 |
| Total Other Finance Cost | $-1,831,083 | $343,328 | $9,040,971 | $3,089,952 |
| Interest Expense Non Operating | $16,250,859 | $19,340,811 | $8,583,200 | $21,629,665 |
| Operating Expense | $3,283,131,317 | $3,340,810,423 | $2,682,078,414 | $2,302,357,635 |
| Other Operating Expenses | $75,188,834 | $-54,589,154 | $-30,441,750 | $-75,989,933 |
| Selling And Marketing Expense | $125,886,937 | $77,706,573 | $71,755,554 | $68,093,389 |
| General And Administrative Expense | $673,151,785 | $737,926,336 | $600,137,361 | $551,270,341 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,300,183,174 | $-761,387,084 | $1,064,660,159 | $10,796,979,258 |
| Net Interest Income | $-14,419,776 | $-19,684,139 | $-8,583,200 | $-21,629,665 |
| Normalized Income | $-940,804,579 | $-816,342,225 | $779,340,850 | $10,239,440,205 |
| Net Income From Continuing And Discontinued Operation | $-1,300,183,174 | $-761,387,084 | $1,064,660,159 | $10,796,979,258 |
| Total Operating Income As Reported | $-1,607,805,071 | $-1,504,120,012 | $790,112,194 | $14,468,643,440 |
| Net Income Common Stockholders | $-1,300,183,174 | $-761,387,084 | $1,064,660,159 | $10,796,979,258 |
| Net Income | $-1,300,183,174 | $-761,387,084 | $1,064,660,159 | $10,796,979,258 |
| Net Income Including Noncontrolling Interests | $-1,300,183,174 | $-761,387,084 | $1,064,660,159 | $10,796,979,258 |
| Net Income Continuous Operations | $-1,300,183,174 | $-761,387,084 | $1,064,660,159 | $10,796,979,258 |
| Pretax Income | $-1,202,563,576 | $-775,577,975 | $1,357,404,509 | $14,825,017,914 |
| Special Income Charges | $-893,682,810 | $-757,152,705 | $-915,541 | $-3,433,280 |
| Operating Income | $-733,234,187 | $-811,856,301 | $1,002,060,019 | $14,080,797,231 |
| Gross Profit | $2,549,897,130 | $2,528,954,122 | $3,684,138,433 | $16,383,154,867 |
| Interest Income | - | $500,801,124 | $409,246,988 | $55,504,695 |
| Interest Income Non Operating | - | $500,801,124 | $409,246,988 | $55,504,695 |
| Depreciation Amortization Depletion Income Statement | - | - | - | - |
| Depreciation And Amortization In Income Statement | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-5.38 | $-3.17 | $4.38 | $43.22 |
| Basic EPS | $-5.38 | $-3.17 | $4.43 | $44.38 |
| Other | ||||
| Tax Effect Of Unusual Items | $-95,531,019 | $1,007,324 | $78,608,381 | $208,311,295 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-293,316,563 | $-471,160,472 | $1,211,947,875 | $14,221,905,044 |
| Total Unusual Items | $-454,909,613 | $55,962,466 | $363,927,691 | $765,850,348 |
| Total Unusual Items Excluding Goodwill | $-454,909,613 | $55,962,466 | $363,927,691 | $765,850,348 |
| Reconciled Depreciation | $438,086,541 | $341,039,157 | $209,887,857 | $141,107,812 |
| EBITDA (Bullshit earnings) | $-748,226,176 | $-415,198,007 | $1,575,875,566 | $14,987,755,391 |
| EBIT | $-1,186,312,717 | $-756,237,163 | $1,365,987,709 | $14,846,647,579 |
| Diluted Average Shares | $276,634,718 | $274,868,983 | $277,752,360 | $285,861,246 |
| Basic Average Shares | $276,634,718 | $274,868,983 | $275,349,064 | $278,416,174 |
| Diluted NI Availto Com Stockholders | $-1,300,183,174 | $-761,387,084 | $1,064,660,159 | $10,796,979,258 |
| Tax Provision | $97,619,598 | $-14,190,891 | $292,744,350 | $4,028,038,656 |
| Other Special Charges | $903,524,880 | $752,346,113 | $33,646,145 | $3,433,280 |
| Write Off | $7,324,331 | $4,806,592 | $915,541 | - |
| Restructuring And Mergern Acquisition | $-17,166,400 | $0 | $0 | - |
| Gain On Sale Of Security | $438,773,197 | $813,115,170 | $364,843,232 | $769,283,628 |
| Research And Development | $2,408,903,761 | $2,579,766,667 | $2,040,627,249 | $1,758,983,838 |
| Selling General And Administration | $799,038,722 | $815,632,909 | $671,892,916 | $619,363,730 |
| Other Gand A | $673,151,785 | $737,926,336 | $600,137,361 | $551,270,341 |
| Insurance And Claims | - | - | - | $24,376,289 |
| Salaries And Wages | - | - | - | $175,898,384 |
| Minority Interests | - | - | - | - |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $19,741,703,903 | $20,874,457,451 | $21,834,860,337 | $22,700,733,579 |
| Total Assets | $25,164,340,936 | $25,783,590,223 | $26,329,023,988 | $26,641,223,592 |
| Total Non Current Assets | $6,685,740,781 | $4,264,362,770 | $3,981,460,489 | $1,553,101,475 |
| Other Non Current Assets | $8,354,315 | $30,098,422 | $95,445,187 | $7,438,774 |
| Non Current Deferred Assets | $15,449,760 | $93,499,661 | $93,041,891 | $262,760,370 |
| Non Current Deferred Taxes Assets | $15,449,760 | $93,499,661 | $93,041,891 | $262,760,370 |
| Non Current Accounts Receivable | $2,288,853 | $11,215,382 | - | - |
| Investmentin Financial Assets | $2,923,094,677 | $1,435,111,082 | $1,345,960,242 | $91,783,021 |
| Goodwill And Other Intangible Assets | $2,258,983,863 | $1,340,123,666 | $1,335,088,188 | $251,430,546 |
| Other Intangible Assets | $1,837,949,280 | $904,554,864 | $920,233,509 | $181,391,632 |
| Current Assets | $18,478,600,154 | $21,519,227,453 | $22,347,563,499 | $25,088,122,117 |
| Other Current Assets | $198,901,360 | $243,419,559 | $321,469,460 | $311,169,620 |
| Inventory | $126,688,036 | $324,216,084 | $409,361,431 | $503,089,977 |
| Receivables | $1,127,145,857 | $1,743,991,848 | $2,677,615,150 | $8,178,073,198 |
| Other Receivables | $9,269,856 | $11,444,267 | $5,607,691 | - |
| Taxes Receivable | $60,196,844 | $57,221,335 | $204,966,822 | $457,771 |
| Accounts Receivable | $1,057,679,156 | $1,675,326,246 | $2,467,040,637 | $8,177,615,428 |
| Cash Cash Equivalents And Short Term Investments | $17,025,864,901 | $19,207,599,962 | $18,939,117,458 | $16,095,789,322 |
| Cash And Cash Equivalents | $8,783,932,693 | $11,171,779,003 | $13,348,249,701 | $15,879,034,905 |
| Cash Equivalents | $7,837,262,927 | $10,656,786,988 | $12,829,709,963 | $14,362,440,642 |
| Cash Financial | $946,669,766 | $514,992,015 | $518,539,738 | $1,516,594,263 |
| Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $306,019,700 | $290,913,267 | $250,743,890 | $242,847,346 |
| Long Term Debt And Capital Lease Obligation | $246,280,626 | $245,708,412 | $218,585,500 | $201,647,985 |
| Long Term Debt | $246,280,626 | $245,708,412 | $218,585,500 | $201,647,985 |
| Current Debt And Capital Lease Obligation | $59,739,074 | $45,204,855 | $32,158,390 | $41,199,361 |
| Current Debt | $59,739,074 | $45,204,855 | $32,158,390 | $41,199,361 |
| Other Current Borrowings | $59,739,074 | $45,204,855 | $32,158,390 | $41,199,361 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,163,653,169 | $3,569,009,107 | $3,159,075,463 | $3,689,059,467 |
| Total Non Current Liabilities Net Minority Interest | $711,947,850 | $681,391,657 | $789,539,980 | $312,314,046 |
| Other Non Current Liabilities | $227,855,356 | $153,810,948 | $59,395,746 | $26,436,257 |
| Non Current Deferred Liabilities | $197,184,720 | $257,953,778 | $501,487,780 | $62,485,698 |
| Non Current Deferred Taxes Liabilities | $96,475,171 | $48,523,692 | $45,433,740 | $7,095,446 |
| Current Liabilities | $2,451,705,319 | $2,887,617,449 | $2,369,535,482 | $3,376,745,421 |
| Other Current Liabilities | $674,525,097 | $1,845,731,382 | $618,333,746 | $1,883,611,906 |
| Current Deferred Liabilities | $863,927,716 | $337,491,434 | $404,325,953 | $88,235,299 |
| Payables And Accrued Expenses | $687,228,233 | $493,476,793 | $1,006,523,283 | $915,541,360 |
| Payables | $687,228,233 | $493,476,793 | $1,006,523,283 | $915,541,360 |
| Total Tax Payable | $75,074,392 | $5,149,920 | $601,396,231 | $681,963,871 |
| Income Tax Payable | $75,074,392 | $5,149,920 | $601,396,231 | $681,963,871 |
| Accounts Payable | $612,153,842 | $488,326,873 | $405,127,052 | $233,577,489 |
| Tradeand Other Payables Non Current | - | - | $0 | $11,902,038 |
| Equity | ||||
| Common Stock Equity | $22,000,687,766 | $22,214,581,116 | $23,169,948,526 | $22,952,164,125 |
| Total Equity Gross Minority Interest | $22,000,687,766 | $22,214,581,116 | $23,169,948,526 | $22,952,164,125 |
| Stockholders Equity | $22,000,687,766 | $22,214,581,116 | $23,169,948,526 | $22,952,164,125 |
| Gains Losses Not Affecting Retained Earnings | $-1,673,495,163 | $-1,516,937,591 | $-1,126,802,529 | $-971,503,826 |
| Other Equity Adjustments | $-1,673,495,163 | $-1,516,937,591 | $-1,126,802,529 | $-971,503,826 |
| Retained Earnings | $20,556,077,943 | $21,856,261,117 | $22,617,648,200 | $21,552,988,041 |
| Other | ||||
| Treasury Shares Number | $8,814,543 | $9,820,779 | $12,390,096 | $6,107,841 |
| Ordinary Shares Number | $287,623,429 | $274,628,995 | $272,059,678 | $278,341,933 |
| Share Issued | $296,437,972 | $284,449,774 | $284,449,774 | $284,449,774 |
| Tangible Book Value | $19,741,703,903 | $20,874,457,451 | $21,834,860,337 | $22,700,733,579 |
| Invested Capital | $22,306,707,466 | $22,505,494,384 | $23,420,692,416 | $23,195,011,470 |
| Working Capital | $16,026,894,835 | $18,631,610,004 | $19,978,028,017 | $21,711,376,696 |
| Total Capitalization | $22,246,968,392 | $22,460,289,529 | $23,388,534,025 | $23,153,812,109 |
| Treasury Stock | $8,812,086 | $9,842,070 | $12,359,808 | $6,065,462 |
| Additional Paid In Capital | $2,830,510,557 | $1,600,595,183 | $1,406,958,185 | $2,092,240,893 |
| Capital Stock | $296,406,515 | $284,504,478 | $284,504,478 | $284,504,478 |
| Common Stock | $296,406,515 | $284,504,478 | $284,504,478 | $284,504,478 |
| Non Current Deferred Revenue | $100,709,550 | $209,430,086 | $456,054,040 | $55,390,252 |
| Long Term Provisions | $40,627,148 | $23,918,518 | $10,070,955 | $9,842,070 |
| Current Deferred Revenue | $863,927,716 | $337,491,434 | $404,325,953 | $88,235,299 |
| Current Provisions | $166,285,200 | $165,712,986 | $308,194,110 | $448,157,496 |
| Investments And Advances | $2,923,094,677 | $1,435,111,082 | $1,345,960,242 | $91,783,021 |
| Available For Sale Securities | $2,923,094,677 | $1,435,111,082 | $1,345,960,242 | $91,783,021 |
| Goodwill | $421,034,583 | $435,568,802 | $414,854,679 | $70,038,914 |
| Net PPE | $1,477,569,312 | $1,354,314,557 | $1,111,924,982 | $939,688,763 |
| Accumulated Depreciation | $-544,174,896 | $-368,963,168 | $-242,389,575 | $-133,096,825 |
| Gross PPE | $2,021,744,208 | $1,723,277,725 | $1,354,314,557 | $1,072,785,589 |
| Construction In Progress | $547,608,176 | $527,122,938 | $445,754,200 | $269,512,488 |
| Other Properties | $571,641,137 | $500,801,124 | $399,061,590 | $318,608,393 |
| Buildings And Improvements | $231,403,079 | $272,602,440 | $240,100,722 | $236,324,114 |
| Land And Improvements | $671,091,817 | $422,751,223 | $269,398,045 | $248,340,594 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $6,752,118 | $9,040,971 | $7,095,446 | $10,185,398 |
| Work In Process | $7,667,659 | $8,354,315 | $4,577,707 | $24,032,961 |
| Raw Materials | $112,268,259 | $306,820,798 | $397,688,278 | $468,871,619 |
| Other Short Term Investments | $8,241,932,208 | $8,035,820,959 | $5,590,867,758 | $216,754,417 |
| Machinery Furniture Equipment | - | - | - | - |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-335,317,023 | $-279,926,771 | $5,339,780,540 | $15,122,568,856 |
| Operating Activities | ||||
| Operating Cash Flow | $521,858,575 | $237,697,426 | $6,147,173,576 | $15,538,339,077 |
| Cash Flow From Continuing Operating Activities | $521,858,575 | $237,697,426 | $6,147,173,576 | $15,538,339,077 |
| Operating Gains Losses | $-22,316,321 | $-120,393,689 | $-135,843,449 | $440,718,722 |
| Investing Activities | ||||
| Capital Expenditure | $-857,175,598 | $-517,624,196 | $-807,393,037 | $-415,770,220 |
| Investing Cash Flow | $-2,825,017,309 | $-2,381,780,848 | $-7,958,915,485 | $-40,398,263 |
| Cash Flow From Continuing Investing Activities | $-2,825,017,309 | $-2,381,780,848 | $-7,958,915,485 | $-40,398,263 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $0 | $-845,159,118 | $-1,128,862,497 |
| Financing Cash Flow | $-60,540,172 | $-52,529,186 | $-891,050,629 | $-1,624,284,815 |
| Cash Flow From Continuing Financing Activities | $-60,540,172 | $-52,529,186 | $-891,050,629 | $-1,624,284,815 |
| Net Other Financing Charges | $-2,288,853 | - | - | - |
| Net Common Stock Issuance | $0 | $0 | $-845,159,118 | $-1,002,403,347 |
| Issuance Of Capital Stock | - | $0 | $0 | $126,459,150 |
| Cash Dividends Paid | - | $0 | $0 | $-554,245,851 |
| Common Stock Issuance | - | $0 | $0 | $126,459,150 |
| Other | ||||
| Repayment Of Debt | $-65,918,978 | $-52,529,186 | $-46,234,839 | $-68,551,159 |
| Issuance Of Debt | $7,667,659 | $0 | $343,328 | $915,541 |
| End Cash Position | $8,783,932,693 | $11,171,779,003 | $13,348,249,701 | $15,879,034,905 |
| Other Cash Adjustment Outside Changein Cash | $6,752,118 | $3,204,395 | $188,601,520 | $-572,213 |
| Beginning Cash Position | $11,171,779,003 | $13,348,249,701 | $15,879,034,905 | $1,937,171,075 |
| Effect Of Exchange Rate Changes | $-30,899,521 | $16,937,515 | $-16,594,187 | $68,780,045 |
| Changes In Cash | $-2,363,698,906 | $-2,196,612,608 | $-2,702,792,537 | $13,873,655,999 |
| Common Stock Payments | $0 | $0 | $-845,159,118 | $-1,128,862,497 |
| Net Issuance Payments Of Debt | $-58,251,319 | $-52,529,186 | $-45,891,511 | $-67,635,618 |
| Net Long Term Debt Issuance | $-58,251,319 | $-52,529,186 | $-45,891,511 | $-67,635,618 |
| Long Term Debt Payments | $-65,918,978 | $-52,529,186 | $-46,234,839 | $-68,551,159 |
| Long Term Debt Issuance | $7,667,659 | $0 | $343,328 | $915,541 |
| Net Investment Purchase And Sale | $-2,186,198,325 | $-1,865,529,964 | $-6,765,965,093 | $374,685,302 |
| Sale Of Investment | $10,886,015,656 | $12,291,371,643 | $1,391,966,195 | $429,388,898 |
| Purchase Of Investment | $-13,072,213,981 | $-14,156,901,607 | $-8,157,931,288 | $-54,703,596 |
| Net Business Purchase And Sale | $213,206,694 | $0 | $-385,557,355 | $0 |
| Sale Of Business | $213,206,694 | - | - | $0 |
| Net Intangibles Purchase And Sale | $-656,786,483 | $-189,745,947 | $-521,171,919 | $-39,024,950 |
| Purchase Of Intangibles | $-656,786,483 | $-189,745,947 | $-521,171,919 | $-39,024,950 |
| Net PPE Purchase And Sale | $-195,239,195 | $-326,504,938 | $-286,221,118 | $-376,058,614 |
| Sale Of PPE | $5,149,920 | $1,373,312 | - | $686,656 |
| Purchase Of PPE | $-200,389,115 | $-327,878,250 | $-286,221,118 | $-376,745,270 |
| Taxes Refund Paid | $4,348,821 | $-445,410,872 | $-552,643,653 | $-4,831,883,970 |
| Interest Received Cfo | $385,671,798 | $543,488,240 | $295,490,974 | $33,531,702 |
| Interest Paid Cfo | $-12,588,694 | $-15,449,760 | $-6,179,904 | $-24,605,174 |
| Change In Working Capital | $615,472,679 | $1,396,887,230 | $6,379,949,967 | $5,171,092,044 |
| Change In Payables And Accrued Expense | $-828,336,045 | $867,933,209 | $136,072,335 | $98,077,368 |
| Change In Payable | $-828,336,045 | $867,933,209 | $136,072,335 | $98,077,368 |
| Change In Account Payable | $-828,336,045 | $867,933,209 | $136,072,335 | $98,077,368 |
| Change In Inventory | $203,593,510 | $85,259,789 | $93,728,547 | $71,984,439 |
| Change In Receivables | $1,240,215,215 | $443,694,232 | $6,150,149,086 | $5,001,030,236 |
| Other Non Cash Items | $194,209,211 | $-802,357,559 | $-1,459,716,256 | $-340,924,714 |
| Stock Based Compensation | $121,538,116 | $115,472,654 | $58,823,532 | $124,284,740 |
| Depreciation Amortization Depletion | $438,086,541 | $341,039,157 | $209,887,857 | $141,107,812 |
| Depreciation And Amortization | $438,086,541 | $341,039,157 | $209,887,857 | $141,107,812 |
| Depreciation | $438,086,541 | $341,039,157 | $209,887,857 | $141,107,812 |
| Gain Loss On Investment Securities | $-11,902,038 | $5,264,363 | $200,846,886 | $-275,806,835 |
| Net Foreign Currency Exchange Gain Loss | $-7,553,216 | $-125,314,724 | $-341,039,157 | $715,838,901 |
| Gain Loss On Sale Of PPE | $-2,861,067 | $-343,328 | $4,348,821 | $686,656 |
| Net Income From Continuing Operations | $-1,202,563,576 | $-775,577,975 | $1,357,404,509 | $14,825,017,914 |
| Purchase Of Business | - | $0 | $-385,557,355 | $0 |
| Amortization Cash Flow | - | - | $46,349,281 | $25,177,387 |
| Amortization Of Intangibles | - | - | $46,349,281 | $25,177,387 |
| Changes In Account Receivables | - | - | - | $5,001,030,236 |
Fetched: 2026-07-15